TEAXS – The Food and Drug Administration recently cleared two COVID-19 antiviral drugs, and they’re now available at select Walmart and Sam’s Club pharmacies in Texas.
Pfizer’s Paxlovid and Merck’s molnupiravir require a prescription and will be available while stocks last, Walmart said.
To see if the medications are available at a Walmart or Sam’s Club drugstore near you, click here.
A check carried out on Friday morning showed antiviral drugs available at eight Austin-area stores, 40 Dallas-area drugstores and a handful of drugstores near San Antonio.
Since the drugs are intended for those who have tested positive for COVID-19, they will only be available through curbside pickup or drive-thru drugstore windows.
“We are committed to working with our state and federal partners to provide access to new treatment options such as licensed COVID-19 antiviral drugs, as they become available,” said Kevin Host, vice-president. senior president of pharmacy. “This drug offers clients the opportunity to recover at home and helps reduce the burden on our hospitals and communities.”
Earlier in December, Pfizer announced that its COVID-19 pill is very effective in preventing serious illness and death, and also noted that it is effective against the newly discovered omicron variant – although more studies are needed.
Pfizer said that Paxlovid is 89% effective in reducing the risk of hospitalization or death if given within three days of symptom onset, and 88% if given within five days.
“This news further corroborates that our oral antiviral candidate, if licensed or approved, could have a significant impact on the lives of many people, as the data further supports the effectiveness of PAXLOVID in reducing hospitalizations and deaths and show a substantial decrease in viral load, Albert Bourla, CEO of Pfizer said in a press release. “This highlights the potential of the treatment candidate to save the lives of patients around the world. “
Molnupiravir, a joint effort by Merck and Ridgeback Biotherapeutics, reduced the risk of hospitalization and death in high-risk patients by 30% in a clinical trial.
Merck’s pill has been approved for patients 18 years and older who are at high risk of serious illness from COVID-19 “for whom FDA-approved alternative treatment options to COVID-19 are not accessible or clinically appropriate ”.